Nevada
|
0-30379
|
88-0425691
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 4.01 |
Changes in Registrant’s Certifying Accountant.
|
(a) |
Dismissal of Previous Independent Registered Public Accounting Firm
|
(b)
|
Appointment of New Independent Registered Public Accounting Firm
|
Item 9.01 |
Financial Statements and Exhibits.
|
(d)
|
Exhibit
|
Exhibit No.
|
Description
|
||
Letter dated April 1, 2020 from BDO USA, LLP to the Securities and Exchange Commission
|
Chembio Diagnostics, Inc.
|
||
Dated: April 2, 2020
|
By:
|
/s/ Neil A. Goldman
|
Neil A. Goldman
|
||
Executive Vice President and Chief Financial Officer
|
|
Fax: 631-501-1885
www.bdo.com
|
Melville, NY 11747
|